U.S. Biologics Contract Development Market Size, Share, & Trends Analysis Report By Source (Mammalian, Microbial), By Product Service (Cell-line Development, Process Development), By Indication, And Segment Forecasts, 2025 - 2033

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Source
  • 1.2.2. Product Service
  • 1.2.3. Indication
  • 1.2.4. Estimates and forecasts timeline
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market formulation & Validation
• 1.7. Model Details
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Source Outlook
  • 2.2.2. Product Service Outlook
  • 2.2.3. Indication Outlook
• 2.3. Competitive Insights

Chapter 3. U.S. Biologics Contract Development Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Related/Ancillary Market Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
  • 3.2.2. Market Restraint Analysis
• 3.3. U.S. Biologics Contract Development Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Supplier Power
    • 3.3.1.2. Buyer Power
    • 3.3.1.3. Substitution Threat
    • 3.3.1.4. Threat of New Entrant
    • 3.3.1.5. Competitive Rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political Landscape
    • 3.3.2.2. Technological Landscape
    • 3.3.2.3. Economic Landscape

Chapter 4. U.S. Biologics Contract Development Market: Source Estimates & Trend Analysis

• 4.1. Source Segment Dashboard
• 4.2. U.S. Biologics Contract Development Market: Source Movement Analysis
• 4.3. U.S. Biologics Contract Development Market Size & Trend Analysis, by Source, 2021 - 2033 (USD Million)
  • 4.3.1. Microbial
    • 4.3.1.1. Market Estimates and Forecasts 2021 - 2033 (USD Million)
  • 4.3.2. Mammalian
    • 4.3.2.1. Market Estimates and Forecasts 2021 - 2033 (USD Million)
  • 4.3.3. Others
    • 4.3.3.1. Market Estimates and Forecasts 2021 - 2033 (USD Million)

Chapter 5. U.S. Biologics Contract Development Market: Product Service Estimates & Trend Analysis

• 5.1. Product Service Segment Dashboard
• 5.2. U.S. Biologics Contract Development Market: Product Service Movement Analysis
• 5.3. U.S. Biologics Contract Development Market Size & Trend Analysis, by Product Service, 2021 - 2033 (USD Million)
  • 5.3.1. Cell Line Development
    • 5.3.1.1. Market Estimates and Forecasts 2021 - 2033 (USD Million)
    • 5.3.1.2. Microbial
      • 5.3.1.2.1. Market Estimates and Forecasts 2021 - 2033 (USD Million)
    • 5.3.1.3. Mammalian
      • 5.3.1.3.1. Market Estimates and Forecasts 2021 - 2033 (USD Million)
    • 5.3.1.4. Others
      • 5.3.1.4.1. Market Estimates and Forecasts 2021 - 2033 (USD Million)
  • 5.3.2. Process Development
    • 5.3.2.1. Market Estimates and Forecasts 2021 - 2033 (USD Million)
    • 5.3.2.2. Upstream
      • 5.3.2.2.1. Market Estimates and Forecasts 2021 - 2033 (USD Million)
      • 5.3.2.2.2. Microbial
        • 5.3.2.2.2.1. Market Estimates and Forecasts 2021 - 2033 (USD Million)
      • 5.3.2.2.3. Mammalian
        • 5.3.2.2.3.1. Market Estimates and Forecasts 2021 - 2033 (USD Million)
      • 5.3.2.2.4. Others
        • 5.3.2.2.4.1. Market Estimates and Forecasts 2021 - 2033 (USD Million)
    • 5.3.2.3. Downstream
      • 5.3.2.3.1. Market Estimates and Forecasts 2021 - 2033 (USD Million)
      • 5.3.2.3.2. Bioanalytical Methods
        • 5.3.2.3.2.1. Market Estimates and Forecasts 2021 - 2033 (USD Million)
        • 5.3.2.3.2.2. Impurity, isolation, & identification
          • 5.3.2.3.2.2.1. Market Estimates and Forecasts 2021 - 2033 (USD Million)
        • 5.3.2.3.2.3. Physicochemical characterization
          • 5.3.2.3.2.3.1. Market Estimates and Forecasts 2021 - 2033 (USD Million)
        • 5.3.2.3.2.4. Pharmaceutical analysis
          • 5.3.2.3.2.4.1. Market Estimates and Forecasts 2021 - 2033 (USD Million)
        • 5.3.2.3.2.5. Others
          • 5.3.2.3.2.5.1. Market Estimates and Forecasts 2021 - 2033 (USD Million)
      • 5.3.2.3.3. Product
        • 5.3.2.3.3.1. Market Estimates and Forecasts 2021 - 2033 (USD Million)
        • 5.3.2.3.3.2. MABs
          • 5.3.2.3.3.2.1. Market Estimates and Forecasts 2021 - 2033 (USD Million)
        • 5.3.2.3.3.3. Recombinant proteins
          • 5.3.2.3.3.3.1. Market Estimates and Forecasts 2021 - 2033 (USD Million)
        • 5.3.2.3.3.4. Others
          • 5.3.2.3.3.4.1. Market Estimates and Forecasts 2021 - 2033 (USD Million)

Chapter 6. U.S. Biologics Contract Development Market: Indication Estimates & Trend Analysis

• 6.1. Indication Segment Dashboard
• 6.2. U.S. Biologics Contract Development Market: Indication Movement Analysis
• 6.3. U.S. Biologics Contract Development Market Size & Trend Analysis, by Indication, 2021 - 2033 (USD Million)
  • 6.3.1. Oncology
    • 6.3.1.1. Market Estimates and Forecasts 2021 - 2033 (USD million)
  • 6.3.2. Immunological Disorders
    • 6.3.2.1. Market Estimates and Forecasts 2021 - 2033 (USD Million)
  • 6.3.3. Cardiovascular Disorders
    • 6.3.3.1. Market Estimates and Forecasts 2021 - 2033 (USD Million)
  • 6.3.4. Hematological Disorders
    • 6.3.4.1. Market Estimates and Forecasts 2021 - 2033 (USD Million)
  • 6.3.5. Others
    • 6.3.5.1. Market Estimates and Forecasts 2021 - 2033 (USD Million)

Chapter 7. Competitive Landscape

• 7.1. Recent Developments & Impact Analysis, By Key Market Participants
• 7.2. Company/Competition Categorization
• 7.3. Vendor Landscape
  • 7.3.1. Key company heat map analysis, 2024
• 7.4. Company Profiles
  • 7.4.1. WuXi Biologics.
    • 7.4.1.1. Company overview
    • 7.4.1.2. Financial performance
    • 7.4.1.3. Product benchmarking
    • 7.4.1.4. Strategic initiatives
  • 7.4.2. Abzena
    • 7.4.2.1. Company overview
    • 7.4.2.2. Financial performance
    • 7.4.2.3. Product benchmarking
    • 7.4.2.4. Strategic initiatives
  • 7.4.3. FUJIFILM Diosynth Biotechnologies.
    • 7.4.3.1. Company overview
    • 7.4.3.2. Financial performance
    • 7.4.3.3. Product benchmarking
    • 7.4.3.4. Strategic initiatives
  • 7.4.4. KBI Biopharma
    • 7.4.4.1. Company overview
    • 7.4.4.2. Financial performance
    • 7.4.4.3. Product benchmarking
    • 7.4.4.4. Strategic initiatives
  • 7.4.5. AGC Biologics.
    • 7.4.5.1. Company overview
    • 7.4.5.2. Financial performance
    • 7.4.5.3. Product benchmarking
    • 7.4.5.4. Strategic initiatives
  • 7.4.6. Thermo Fisher Scientific Inc.
    • 7.4.6.1. Company overview
    • 7.4.6.2. Financial performance
    • 7.4.6.3. Product benchmarking
    • 7.4.6.4. Strategic initiatives
  • 7.4.7. Curia Global, Inc.
    • 7.4.7.1. Company overview
    • 7.4.7.2. Financial performance
    • 7.4.7.3. Product benchmarking
    • 7.4.7.4. Strategic initiatives
  • 7.4.8. GenScript
    • 7.4.8.1. Company overview
    • 7.4.8.2. Financial performance
    • 7.4.8.3. Product benchmarking
    • 7.4.8.4. Strategic initiatives
  • 7.4.9. Bionova Scientific LLC
    • 7.4.9.1. Company overview
    • 7.4.9.2. Financial performance
    • 7.4.9.3. Product benchmarking
    • 7.4.9.4. Strategic initiatives
  • 7.4.10. Boehringer Ingelheim International
    • 7.4.10.1. Company overview
    • 7.4.10.2. Financial performance
    • 7.4.10.3. Product benchmarking
    • 7.4.10.4. Strategic initiatives
  • 7.4.11. STC Biologics
    • 7.4.11.1. Company overview
    • 7.4.11.2. Financial performance
    • 7.4.11.3. Product benchmarking
    • 7.4.11.4. Strategic initiatives

List of Tables

• Table 1 List of abbreviations
• Table 2 U.S. biologics contract development market, by source, 2021 - 2033 (USD Million)
• Table 3 U.S. biologics contract development market, by product service, 2021 - 2033 (USD Million)
• Table 4 U.S. biologics contract development market, by indication, 2021 - 2033 (USD Million)

List of Figures

• Fig. 1 Market research process
• Fig. 2 Data triangulation techniques
• Fig. 3 Primary research pattern
• Fig. 4 Primary interviews
• Fig. 5 Market research approaches
• Fig. 6 Value-chain-based sizing & forecasting
• Fig. 7 QFD modeling for market share assessment
• Fig. 8 Market formulation & validation
• Fig. 9 U.S. biologics contract development market: market outlook
• Fig. 10 U.S. biological contract development competitive insights
• Fig. 11 Parent market outlook
• Fig. 12 Related/ancillary market outlook
• Fig. 13 Penetration and growth prospect mapping
• Fig. 14 Industry value chain analysis
• Fig. 15 U.S. biologics contract development market driver impact
• Fig. 16 U.S. biologics contract development market restraint impact
• Fig. 17 U.S. biologics contract development market strategic initiatives analysis
• Fig. 18 U.S. biologics contract development market: source movement analysis
• Fig. 19 U.S. biologics contract development market: source outlook and key takeaways
• Fig. 20 Microbial market estimates and forecast, 2021 - 2033 (USD Million)
• Fig. 21 Mammalian market estimates and forecast, 2021 - 2033 (USD Million)
• Fig. 22 Others estimates and forecast, 2021 - 2033 (USD Million)
• Fig. 23 U.S. biologics contract development market: product service movement analysis
• Fig. 24 U.S. biologics contract development market: product service outlook and key takeaways
• Fig. 25 Cell line development (2-17 years) market estimates and forecast, 2021 - 2033 (USD Million)
• Fig. 26 Microbial market estimates and forecast, 2021 - 2033 (USD Million)
• Fig. 27 Mammalian market estimates and forecast, 2021 - 2033 (USD Million)
• Fig. 28 Others market estimates and forecast, 2021 - 2033 (USD Million)
• Fig. 29 Process development market estimates and forecast, 2021 - 2033 (USD Million)
• Fig. 30 Upstream market estimates and forecast, 2021 - 2033 (USD Million)
• Fig. 31 Microbial market estimates and forecast, 2021 - 2033 (USD Million)
• Fig. 32 Mammalian market estimates and forecast, 2021 - 2033 (USD Million)
• Fig. 33 Others market estimates and forecast, 2021 - 2033 (USD Million)
• Fig. 34 Downstream market estimates and forecast, 2021 - 2033 (USD Million)
• Fig. 35 Analytical methods market estimates and forecast, 2021 - 2033 (USD Million)
• Fig. 36 Impurity, isolation, & identification market estimates and forecast, 2021 - 2033 (USD Million)
• Fig. 37 Physicochemical characterization market estimates and forecast, 2021 - 2033 (USD Million)
• Fig. 38 Pharmaceutical analysis market estimates and forecast, 2021 - 2033 (USD Million)
• Fig. 39 Others market estimates and forecast, 2021 - 2033 (USD Million)
• Fig. 40 Product market estimates and forecast, 2021 - 2033 (USD Million)
• Fig. 41 MABs market estimates and forecast, 2021 - 2033 (USD Million)
• Fig. 42 Recombinant proteins market estimates and forecast, 2021 - 2033 (USD Million)
• Fig. 43 Others market estimates and forecast, 2021 - 2033 (USD Million)
• Fig. 44 U.S. biologics contract development market: indication movement analysis
• Fig. 45 U.S. biologics contract development market: indication outlook and key takeaways
• Fig. 46 Hospital pharmacy estimates and forecast, 2021 - 2033 (USD Million)
• Fig. 47 Oncology market estimates and forecast, 2021 - 2033 (USD Million)
• Fig. 48 Immunological Disorders market estimates and forecast, 2021 - 2033 (USD Million)
• Fig. 49 Cardiovascular Disorders market estimates and forecast, 2021 - 2033 (USD Million)
• Fig. 50 Hematological Disorders market estimates and forecast, 2021 - 2033 (USD Million)
• Fig. 51 Others market estimates and forecast, 2021 - 2033 (USD Million)